AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...
Prescription medication is a lifeline for millions of people around the U.S. Unfortunately, the cost of such medications has ...
MoneyShow presents top investment ideas for 2026 from leading advisors. Part 1 includes AbbVie, Alexandria Real Estate Equities, Arbor Realty, Archer Aviation, Ares Management & Aris Mining.
WISN 12 News on MSN
Trump administration strikes deal with AbbVie to cut costs of certain drugs
The Trump administration has finalized a deal with drugmaker AbbVie to cut the cost of certain medicines, marking the latest ...
Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...
SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost ...
AbbVie reached a deal with the Trump administration on drug prices in exchange for being exempted from tariffs and future ...
AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers ...
The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.
AbbVie commits to lowering Medicaid drug prices and investing $100 billion in US R&D and capital investments over the next decade. The TrumpRx program will expand direct-to-patient offerings, ...
Let's consider three of them: Eli Lilly ( LLY +0.52%), AbbVie ( ABBV 0.31%), and Intuitive Surgical ( ISRG 1.15%). Here's why ...
Maternal exposure to TNF inhibition does not significantly increase infection risk in newborns, according to findings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results